Biogen Inc (NASDAQ:BIIB)

CAPS Rating: 4 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Results 1 - 20 of 104 : 1 2 3 4 5 6 Next »

Recs

0
Member Avatar stocky5 (41.56) Submitted: 5/8/2015 9:58:27 AM : Outperform Start Price: $394.54 BIIB Score: +1.49

BIIB is buying $5B of its stock, and it is coming off a period of oversold condition. The company missed its quarterly earnings in what appears to be a seasonal pattern (same as 2014). This is a fast grower with a great track record selling at a reasonable price.

Recs

0
Member Avatar DrGoldin (99.77) Submitted: 4/28/2015 10:08:05 PM : Outperform Start Price: $377.97 BIIB Score: +5.49

First it was too high. Now it's too low.

Recs

0
Member Avatar andrewtraylor (49.69) Submitted: 4/24/2015 6:14:07 PM : Outperform Start Price: $401.75 BIIB Score: +0.12

Clear buying opportunity

Recs

0
Member Avatar peteypab (48.92) Submitted: 4/24/2015 12:36:43 PM : Outperform Start Price: $404.65 BIIB Score: -0.85

crashing today...alzheimers drug might cash in big

Recs

0
Member Avatar CellBlock9 (89.26) Submitted: 3/29/2015 10:28:03 AM : Outperform Start Price: $433.68 BIIB Score: -9.86

mgk, s&p 4 star, 429.87

Recs

0
Member Avatar quinpeung (41.40) Submitted: 3/24/2015 12:55:19 PM : Outperform Start Price: $459.56 BIIB Score: -13.82

Speculative CAPS run-up play

Recs

0
Member Avatar joaquingrech (98.92) Submitted: 3/23/2015 8:49:54 AM : Outperform Start Price: $448.62 BIIB Score: -11.92

they may have something going on with Alzheimer drugs, highly speculative but I like the trials so far

Recs

1
Member Avatar Cturchi44 (< 20) Submitted: 1/21/2015 5:09:13 PM : Outperform Start Price: $364.00 BIIB Score: +6.42

pipeline

Recs

1
Member Avatar Orffy (58.05) Submitted: 11/20/2014 4:17:10 AM : Outperform Start Price: $300.10 BIIB Score: +30.13

Multiple Sclerosis (MS) is a horrible disease that particularly plagues people living in the Northern Hemisphere (especially North America and Northern Europe). MS is a significant problem that will result in a significant reward for those who can solve its complexities. As of now, the disease has no cure, which means that companies with current research into this disease have an edge on discovering any potential cures. This could be worth many billions of dollars in cash flows for the companies that can accomplish this feat. Biogen Idec has proven itself capable of building effective MS drugs that doctors trust and recommend. With their successful track record and great financials, I see no reason to bet against Biogen Idec. Long-term.

Recs

1
Member Avatar RugbyViking13 (88.86) Submitted: 10/22/2014 9:00:16 PM : Outperform Start Price: $314.00 BIIB Score: +19.03

Staggering numbers from this bio tech company

Recs

1
Member Avatar billmans (< 20) Submitted: 10/22/2014 7:44:45 AM : Outperform Start Price: $300.00 BIIB Score: +24.90

Pipeline!

Recs

0
Member Avatar racoveanul (84.93) Submitted: 7/11/2014 10:17:42 AM : Outperform Start Price: $318.14 BIIB Score: +18.32

I expect at least a point a week from this stock, for the next five years.

Recs

0
Member Avatar TMFFlygal (99.35) Submitted: 7/8/2014 6:47:19 PM : Outperform Start Price: $322.62 BIIB Score: +16.77

Cancer drugs and new MS drug

Recs

0
Member Avatar SnowBawl (< 20) Submitted: 5/15/2014 7:57:08 AM : Outperform Start Price: $295.63 BIIB Score: +23.56

4 Big Elderly. Reeves.

Recs

0
Member Avatar km00nster (< 20) Submitted: 5/8/2014 7:59:02 PM : Outperform Start Price: $320.20 BIIB Score: +11.98

BIIB and GILD are my 2 top holdings. In the long term, this is a no brainer. Very stacked pipeline.

Recs

0
Member Avatar yooperking (45.96) Submitted: 4/2/2014 10:50:16 AM : Outperform Start Price: $312.75 BIIB Score: +16.16

PEG ratio of 1.5, Quarterly revenue growth (yoy) or 38.6% and Quarterly earnings growth (yoy) of 56.5% makes this company's stock a good buy. Institutional ownership of 94.5%, 0.9% insider ownership and a 1.9 short ratio leaves room for more buyers.

Recs

0
Member Avatar TerryFool (69.16) Submitted: 3/10/2014 8:31:23 PM : Outperform Start Price: $297.84 BIIB Score: +19.68

EPS 1YR 25% 2YR 20% 5YR 18%

Recs

0
Member Avatar RideWildfire (29.71) Submitted: 2/11/2014 11:07:00 AM : Outperform Start Price: $315.77 BIIB Score: +9.98

They are delivering relief to a large population in ways that lead their competitors.

Recs

1
Member Avatar TerryHoodSr (77.88) Submitted: 7/21/2013 1:30:37 AM : Outperform Start Price: $289.85 BIIB Score: +25.71

growth

Recs

1
Member Avatar sugarmag23 (< 20) Submitted: 6/5/2013 11:47:30 AM : Outperform Start Price: $215.34 BIIB Score: +56.01

this company will keep coming up with a succession of innovative drugs to treat deadly diseases.

Results 1 - 20 of 104 : 1 2 3 4 5 6 Next »

Featured Broker Partners


Advertisement